Back
Y-mAbs Therapeutics 10K Form
Buy
59
YMAB
Y-mAbs Therapeutics
Last Price:
14.00
Seasonality Move:
-10.6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive YMAB News And Ratings
See the #1 stock for the next 7 days that we like better than YMAB
YMAB Financial Statistics
Sales & Book Value
Annual Sales: | $84.82M |
---|---|
Cash Flow: | $298K |
Price / Cash Flow: | 0 |
Annual Sales: | $2.14 |
Price / Book: | 6.34 |
Profitability
EPS (TTM): | -0.56000 |
---|---|
Net Income (TTM): | $-24.61M |
Gross Margin: | $73.4M |
Return on Equity: | -24.6% |
Return on Assets: | -18.75% |
Y-mAbs Therapeutics Earnings Forecast
Key Y-mAbs Therapeutics Financial Ratios
- The Gross Profit Margin over the past 5 years for YMAB is 86.54%.
- The Selling, General & Administrative Expenses for YMAB have been equal to 52.88% of Gross Profit Margin.
- The Research & Development expenses have been 63.92% of Revenue.
- The Interest Expense is -0.79% of Operating Income.
- The Net Earning history of YMAB is -25.26% of Total Revenues.
- Per Share Earnings over the last 8 years have been positive in 2 years.
Y-mAbs Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | YMAB |
CUSIP: | 984241 |
Website: | ymabs.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 2.92 |
Quick Ratio: | 2.67 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
YMAB Technical Analysis vs Fundamental Analysis
Buy
59
Y-mAbs Therapeutics (YMAB)
is a Buy
Is Y-mAbs Therapeutics a Buy or a Sell?
-
Y-mAbs Therapeutics stock is rated a Buy
The current Y-mAbs Therapeutics [YMAB] share price is $13.57. The Score for YMAB is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.